PLAU and prostate carcinoma: We have also shown that targeting methyl-CpG-binding domain protein 2 (MBD2), a protein that can read the DNA methylation marks and is frequently upregulated in many cancers [85], using a 20-mer antisense oligonucleotide (ASO) reduced uPA gene expression in breast and prostate cancer cells [77,78].